Amarin
AMRN
Performance
About Amarin
Amarin is a global pharmaceutical company focused on cardiovascular health, pursuing therapies to cost-effectively address cardiovascular disease and improve patient outcomes worldwide. The company emphasizes scientific breakthroughs and has developed products and pipeline programs aimed at lipid management and cardiovascular protection. It operates with a global footprint, providing information and updates through investor relations, science and health channels, and patient-focused resources. Amarin brands include VASCEPA and REDUCE-IT-related initiatives, reflecting its commitment to advancing cardiovascular care globally.
Recent News
Justices Poised to Protect Generics Manufacturers From Liability for Decisions of Pharmacists About Prescribing Their Products
Amarin V. Hikma: Settling the Skinny Label Question
Hikma and Amarin's Generic Drug Case Heads to Supreme Court Arguments
Disc’s FDA Meeting Sets ‘Clear Path’ for Embattled Rare Blood Disease Drug
Pharmaceutical Executive Daily: Supreme Court Unanimously Rules in Favor of Hikma Pharmaceuticals in Skinny Label Case
U.S. Supreme Court Holds Generic Manufacturer's "Skinny Label" And Marketing Did Not Induce Patent Infringement
Hikma V. Amarin: The Amici Speak – Part II
The Fatal Conceit of Cheap Drugs
Høeg Fired in Latest FDA Shakeup; 20 People Die After Taking Amgen Drug
U.S. Supreme Court Sides with Generic Drug Maker for Severe Hypertriglyceridemia Agent Icosapent Ethyl
The Skinny on Skinny Labels: The Active Inducement Problem That Patent Practitioners Should Know
How a Supreme Court Fight over Fish Oil Could Raise Your Prescription Drug Costs
Hikma V. Amarin: What the Supreme Court’s Decision Means for Pleading Induced Infringement
Justices Reject Holding Generic Pharmaceutical Manufacturers Liable for Decisions of Pharmacists About Prescribing Their Products
Recent Deals
No recent deals for this company.